Evidence map›Paper›PMID 22626807›Full record

ArticleThe American journal of pathology2012

Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.

Michelle Wilkison, Katherine Gauss, Yanchao Ran, Steve Searles, David Taylor, Nicole Meissner

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014
    Article
  6. Article
  7. Bone effects of biologic drugs in rheumatoid arthritis.Clinical & developmental immunology · 2013
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Michelle WilkisonDepartment of Immunology and Infectious Diseases, Montana State University, Bozeman, MT, USA.
Katherine Gauss
Yanchao Ran
Steve Searles
David Taylor
Nicole Meissner
Montana State University · US

Funding

VIRUSES: FROM PARTICLES TO PROTEOMICSP20RR020185 · NCRR · MONTANA STATE UNIVERSITY - BOZEMAN · PI MEISSNER, NICOLE · 2004 to 2011
$17.0M
Immune response to Pneumocystis and bone marrow failureR01HL090488 · NHLBI · MONTANA STATE UNIVERSITY - BOZEMAN · PI MEISSNER, NICOLE · 2009 to 2013
$1.8M
NCRR NIH HHS 2P20RR020185-06NCRR NIH HHS P20 RR020185NHLBI NIH HHS R01 HL090488NHLBI NIH HHS R01HL090488
6 · The paper itself

Abstract

HIV infection causes loss of CD4(+) T cells and type 1 interferon (IFN)-producing and IFN-responsive dendritic cells, resulting in immunodeficiencies and susceptibility to opportunistic infections, such as Pneumocystis. Osteoporosis and bone marrow failure are additional unexplained complications in HIV-positive patients and patients with AIDS, respectively. We recently demonstrated that mice that lack lymphocytes and IFN a/b receptor (IFrag(-/-)) develop bone marrow failure after Pneumocystis lung infection, whereas lymphocyte-deficient, IFN α/β receptor-competent mice (RAG(-/-)) had normal hematopoiesis. Interestingly, infected IFrag(-/-) mice also exhibited bone fragility, suggesting loss of bone mass. We quantified bone changes and evaluated the potential connection between progressing bone fragility and bone marrow failure after Pneumocystis lung infection in IFrag(-/-) mice. We found that Pneumocystis infection accelerated osteoclastogenesis as bone marrow failure progressed. This finding was consistent with induction of osteoclastogenic factors, including receptor-activated nuclear factor-κB ligand and the proapoptotic factor tumor necrosis factor-related apoptosis-inducing ligand, in conjunction with their shared decoy receptor osteoprotegerin, in the bone marrow of infected IFrag(-/-) mice. Deregulation of this axis has also been observed in HIV-positive individuals. Biphosphonate treatment of IFrag(-/-) mice prevented bone loss and protected loss of hematopoietic precursor cells that maintained activity in vitro but did not prevent loss of mature neutrophils. Together, these data show that bone loss and bone marrow failure are partially linked, which suggests that the deregulation of the receptor-activated nuclear factor-κB ligand/osteoprotegerin/tumor necrosis factor-related apoptosis-inducing ligand axis may connect the two phenotypes in our model.

Indexed as

Anemia, AplasticAnimalsBone Density Conservation AgentsBone MarrowBone Marrow DiseasesBone Marrow Failure DisordersCell DifferentiationCytokinesDiphosphonatesDisease ProgressionFemurHemoglobinuria, ParoxysmalInterferon Type IMiceMice, KnockoutMice, SCIDBone Density Conservation AgentsCytokinesDiphosphonatesInterferon Type IOsteoprotegerinRANK LigandTNF-Related Apoptosis-Inducing LigandTnfrsf11b protein, mouseTnfsf10 protein, mouseTnfsf11 protein, mouse

Identifiers

PMID22626807
PMCPMC3388152
OpenAlexW1989203051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.